Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Xilio Therapeutics, Inc.NASDAQ: XLO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables outflow grows to $5M
Q1 FY2026 accounts receivables was $5M, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $17.5M.
Context
- Accounts receivables amounted to 11.4% of revenue in FY2025, up 11.4 pp from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $5M or moves back toward the trailing-twelve-month quarterly average of $4.38M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (5M) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5M) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 accounts receivables of $17.5M is the largest of the 4 companies compared; the peer median is $0.
- Accounts receivables amounts to 32.7% of revenue for XLO, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.5M | — | — | 32.7% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding XLO) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Deferred Income Tax | 222K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Change in Working Capital | (11.8M) | 2M | (1.66M) | 31.78M | 25.13M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.82M) | 485K | (2.06M) | 1.53M | 152K |
| Other Working Capital | (8.99M) | 1.52M | 405K | 30.26M | 29.97M |
| Other Non-Cash Items | 173K | 224K | 160K | 3K | (3.56M) |
| Operating Cash Flow | (80.75M) | (75.72M) | (68.62M) | (18.38M) | (4.99M) |
| Capital Expenditures | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Debt Repayment | (110K) | (85K) | (6.75M) | (3.38M) | 0 |
| Common Stock Issued | 116.36M | 16K | 202K | 6.83M | 87.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (467K) | 0 | 0 | 25.75M | 0 |
| Financing Cash Flow | 260.67M | (69K) | (6.55M) | 29.2M | 87.78M |
| Effect of Forex Changes | 0 | (9K) | (25K) | 0 | 0 |
| Net Change in Cash | 178.82M | (77.67M) | (75.68M) | 10.78M | 82.27M |
| Free Cash Flow | (81.85M) | (77.59M) | (69.11M) | (18.41M) | (5.51M) |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.